06855.HK
Ascentage Pharma Group International Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 27.20
−3.61%Year over year
Reported trailing growth
- Revenue
- +62.0%
- EBITDA
- -25.9%
- EBIT
- -23.5%
- EPS
- -9.6%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +18.6%
- EBITDA
- +81.9%
- EPS
- +74.2%
Three-year CAGR
- Revenue
- +38.7%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026